Afrogheh Amir H, Meserve Emily, Sadow Peter M, Stephen Antonia E, Nosé Vânia, Berlin Suzanne, Faquin William C
Department of Pathology, Massachusetts General Hospital, Boston, MA, 02114, USA.
Harvard Medical School, Boston, MA, 02114, USA.
Endocr Pathol. 2016 Sep;27(3):213-9. doi: 10.1007/s12022-015-9412-5.
Tumor-to-tumor metastasis is rare. Herein, we present a unique case of endometrial endometrioid adenocarcinoma metastatic to a thyroid Hürthle cell adenoma 9 years after initial diagnosis. On histologic examination of the thyroid, the malignant endometrioid glands and single cells (donor tumor) were dispersed within the Hürthle cell adenoma (recipient tumor). In several sections of the adenoma with still preserved microfollicular architecture, malignant endometrial adenocarcinoma cells were admixed within oncocytic adenomatous epithelium (so-called "cancerization of the follicles"). This unusual phenomenon, to our knowledge, is a novel finding in the thyroid gland. Immunohistochemistry, subsequently elicited clinical history, and morphologic comparison of the tumor in the thyroid to the primary endometrial tumor confirmed the origin of the donor tumor cells. Molecular analysis of both the metastatic and primary endometrial tumors demonstrated PIK3CA and PTEN mutations in both tumors, as is characteristic of well-differentiated endometrioid tumors of the endometrium. Amplification of chromosome 1q was detected in both sites; however, only the metastatic tumor showed loss of chromosomes 2, 9, and 22. The morphologic differential diagnosis of metastatic endometrioid adenocarcinoma in the thyroid includes columnar cell variant of papillary thyroid carcinoma (CCVPTC) arising in a preexisting adenoma, endocrine glandular atypia within an adenoma, and metastasis from other anatomic sites. Histomorphologic differences among these entities may be subtle; therefore, knowledge of and morphologic comparison with prior malignancies and immunohistochemistry can be helpful in rendering the correct diagnosis.
肿瘤转移至肿瘤的情况罕见。在此,我们报告一例独特病例,患者为子宫内膜样腺癌,在初次诊断9年后转移至甲状腺嗜酸性细胞腺瘤。对甲状腺进行组织学检查时,恶性子宫内膜样腺体和单个细胞(供体肿瘤)散布于嗜酸性细胞腺瘤(受体肿瘤)内。在腺瘤仍保留微滤泡结构的几个切片中,恶性子宫内膜腺癌细胞与嗜酸性腺瘤上皮细胞混合存在(所谓的“滤泡癌变”)。据我们所知,这种不寻常的现象在甲状腺中是一项新发现。免疫组织化学检查、随后了解到的临床病史以及将甲状腺肿瘤与原发性子宫内膜肿瘤进行形态学比较,均证实了供体肿瘤细胞的来源。对转移性和原发性子宫内膜肿瘤进行分子分析显示,两个肿瘤均存在PIK3CA和PTEN突变,这是子宫内膜高分化子宫内膜样肿瘤的特征。在两个部位均检测到1号染色体q臂扩增;然而,只有转移性肿瘤显示2号、9号和22号染色体缺失。甲状腺转移性子宫内膜样腺癌的形态学鉴别诊断包括起源于先前存在腺瘤的甲状腺乳头状癌柱状细胞变体(CCVPTC)、腺瘤内的内分泌腺异型性以及来自其他解剖部位的转移。这些实体之间的组织形态学差异可能很细微;因此,了解既往恶性肿瘤情况并与其进行形态学比较以及免疫组织化学检查有助于做出正确诊断。